| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/HIS.12247 |
| P698 | PubMed publication ID | 24117939 |
| P50 | author | Frédérique Penault-Llorca | Q30728827 |
| Magali Lacroix-Triki | Q41608027 | ||
| Jocelyne Jacquemier | Q42215390 | ||
| P2093 | author name string | Anne Cayre | |
| Thomas Filleron | |||
| Gaëtan Macgrogan | |||
| Laurent Arnould | |||
| Magali Lacroix-Triki | |||
| Camille Franchet | |||
| Eveline Mounié | |||
| P2860 | cites work | Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 | Q24657145 |
| The Measurement of Observer Agreement for Categorical Data | Q26778373 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event | Q28245213 | ||
| Fast and non-toxic in situ hybridization without blocking of repetitive sequences | Q28728860 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples | Q30959521 | ||
| Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. | Q31135538 | ||
| Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer | Q33504464 | ||
| Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens | Q33794421 | ||
| Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma | Q34064466 | ||
| HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH) | Q34102078 | ||
| HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations | Q34202609 | ||
| HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases. | Q34467947 | ||
| Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 | Q35130819 | ||
| Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study | Q36458767 | ||
| Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer | Q36648916 | ||
| American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer | Q36678853 | ||
| HER2 testing in the UK: further update to recommendations | Q37125334 | ||
| ASCO-CAP guidelines for breast predictive factor testing: an update | Q37956940 | ||
| Testing HER2 in breast cancer: a comparative study on BRISH, FISH, and IHC. | Q38410942 | ||
| Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours | Q38437057 | ||
| Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer | Q38444766 | ||
| Visualization of FISH Probes by dual-color chromogenic in situ hybridization | Q43186689 | ||
| Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis | Q43294276 | ||
| mRNA in situ hybridization (HistoSonda): a new diagnostic tool for HER2-status in breast cancer-a multicentric Spanish study. | Q44383595 | ||
| In vivo biocompatibility and biodegradation of poly(ethylene carbonate). | Q44673522 | ||
| Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome. | Q46017247 | ||
| Her2 amplification: correlation of chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization | Q46408235 | ||
| Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing. | Q50992951 | ||
| Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of A | Q51912802 | ||
| Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry. | Q51944793 | ||
| Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. | Q51953747 | ||
| Evaluating HER2 amplification and overexpression in breast cancer. | Q52936177 | ||
| Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility. | Q53067130 | ||
| Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. | Q54515786 | ||
| Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH). | Q54538229 | ||
| [Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]. | Q54634889 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 274-283 | |
| P577 | publication date | 2013-10-01 | |
| P1433 | published in | Histopathology | Q1524040 |
| P1476 | title | Instant-quality fluorescence in-situ hybridization as a new tool for HER2 testing in breast cancer: a comparative study | |
| P478 | volume | 64 |
| Q38612634 | Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens |
| Q27015506 | Quantification of HER family receptors in breast cancer |
| Q55068762 | Rapid fluorescence in situ hybridisation (FISH) for HER2 (ERBB2) assessment in breast and gastro-oesophageal cancer. |
| Q55026325 | The FlexISH assay brings flexibility to cytogenetic HER2 testing. |
| Q33692695 | The human epidermal growth factor receptor 2 screening tests for breast cancer suggested by the new updated recommendation of the american society of clinical oncology/college of american pathologists will involve a rise of the in-situ [...] |
Search more.